A Study of BGB-11417 in Participants With Myeloid Malignancies

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

Trial Details

NCT ID
NCT04771130
Phase
PHASE1 / PHASE2
Sponsor
BeOne Medicines
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • BGB-11417
  • Azacitidine
  • Posaconazole
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Tampa, Florida, United States|27.94752,-82.45843
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
  • Houston, Texas, United States|29.76328,-95.36327
  • Milwaukee, Wisconsin, United States|43.0389,-87.90647

Key Eligibility Criteria

  • Confirmed diagnosis of one of the following by 2016 World Health Organization criteria:
  • AML, nonacute promyelocytic leukemia
  • Eastern Cooperative Oncology Group performance status of 0 to 2.
  • Adequate organ function defined as:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →